<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">VASOPRESSIN INJECTION <img border="0" src="../images/pr.gif"/></span><br/>(vay-soe-press'in)<br/><span class="topboxtradename">Pitressin<br/></span><b>Classifications:</b> <span class="classification">hormones and synthetic substitutes</span>; <span class="classification">pituitary (antidiuretic)</span><br/><b>Pregnancy Category: </b>X<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>20 pressor units/mL injection</p>
<h1><a name="action">Actions</a></h1>
<p>Polypeptide hormone extracted from animal posterior pituitaries. Possesses pressor and antidiuretic (ADH) properties, but
         is relatively free of oxytocic properties. Produces concentrated urine by increasing tubular reabsorption of water (ADH activity),
         thus preserving up to 90% of water.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>May increase sodium and decrease potassium reabsorption but plays no causative role in edema formation. Small doses may produce
         anginal pain; large doses may precipitate MI, decrease heart rate and cardiac output, and increase pulmonary arterial pressure
         and BP. The tannate (in peanut oil) is preferred for chronic therapy; intranasal aqueous vasopressin is effective for daily
         maintenance of mild diabetes insipidus. Effective in the treatment of antidiuresis caused by diabetes insipidus.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Antidiuretic to treat diabetes insipidus, to dispel gas shadows in abdominal roentgenography, and as prevention and treatment
         of postoperative abdominal distension. Also given to treat transient polyuria due to ADH deficiency (related to head injuries
         or to neurosurgery).
      </p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Test for differential diagnosis of nephrogenic, psychogenic, and neurohypophyseal diabetes insipidus; test to elevate ability
         of kidney to concentrate urine, and provocative test for pituitary release of corticotropin and growth hormone; emergency
         and adjunct pressor agent in the control of massive GI hemorrhage (e.g., esophageal varices).
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Chronic nephritis accompanied by nitrogen retention; ischemic heart disease, PVCs, advanced arteriosclerosis; pregnancy (category
         X); during first stage of labor.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Epilepsy; migraine; asthma; heart failure, angina pectoris; any state in which rapid addition to extracellular fluid may be
         hazardous; vascular disease; preoperative and postoperative polyuric patients, kidney disease; goiter with cardiac complications;
         older adult patients, children, lactation.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Diabetes Insipidus</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IM/SC</span> 510 U aqueous solution 24 times/d (560 U/d) or 1.252.5 U in oil q23d <b>Intranasal</b> Apply to cotton pledget or intranasal spray<br/><span class="rdage">Child:</span> <span class="rdroute">IM/SC</span> 2.510 U aqueous solution 24 times/d<br/><br/><span class="indicationtitle">Abdominal Distention, Abdominal Radiographic Procedures</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IM/SC</span> 5 U with 510 U q34h prn or 515 U 2 h and 30 min prior to procedure<br/><br/><span class="indicationtitle">GI Hemorrhage</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span> 0.11 U/mL at 0.20.4 U/min up to 0.9 U/min<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Intramuscular/</span><span class="adminroutetype">Subcutaneous</span><br/><ul>
<li>Give 12 glasses of water with vasopressin to reduce adverse effects of tannate and improve therapeutic response.</li>
<li>Do <small>NOT</small> administer vasopressin tannate via IV. Warm ampul to body temperature and shake vigorously to disperse active principle before
            withdrawing drug for IM administration.
         </li>
<li>The tannate injection is often painful, and allergic reactions may develop. It is preferred for use in chronic therapy because
            of its longer duration of action.
         </li>
</ul>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><p><span class="routemethod">PREPARE:</span> <span class="methodtype">IV Infusion:</span> Give vasopressin aqueous injection by continuous IV. Dilute with NS or D5W to a concentration of 0.11 U/mL.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">IV Infusion:</span> Titrate dose and rate to patient's response.  
               </p>
</td>
</tr>
</table>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Skin:</span> Rash, urticaria. <span class="typehead">Body as a Whole:</span>
<span class="speceff-life">Anaphylaxis</span>; <span class="speceff-common">tremor,</span> sweating, bronchoconstriction, <span class="speceff-common">circumoral and facial pallor,</span> angioneurotic edema, <span class="speceff-common">pounding in head, water intoxication</span> (especially with tannate), gangrene at injection site with intraarterial infusion. <span class="typehead">GI:</span>
<span class="speceff-common">Eructations, passage of gas, nausea, vomiting,</span> heartburn, abdominal cramps, increased bowel movements secondary to excessive use. <span class="typehead">CV:</span> Angina (in patient with coronary vascular disease); <span class="speceff-life">cardiac arrest</span>, hypertension, bradycardia, minor arrhythmias, premature atrial contraction, heart block, peripheral vascular collapse, coronary
      insufficiency, <span class="speceff-life">MI</span>; cardiac arrhythmia, pulmonary edema, bradycardia (with intraarterial infusion). <span class="typehead">Urogenital:</span> Uterine cramps. <span class="typehead">Respiratory:</span> Congestion, rhinorrhea, irritation, mucosal ulceration and pruritus, postnasal drip.  <span class="typehead">Special Senses:</span> Conjunctivitis. 
      <h1><a name="dtintefer">Diagnostic Test Interference</a></h1>
<p>Vasopressin increases <span class="alt">plasma cortisol</span> levels.
      </p>
<h1><a name="interactions">Interactions</a></h1><span class="typehead"> Drug:</span>
<b> Alcohol,</b>
<b>demeclocycline,</b>
<b>epinephrine,</b>
<b>heparin,</b>
<b>lithium,</b>
<b>phenytoin</b> may decrease antidiuretic effects of vasopressin; <b>guanethidine,</b>
<b>neostigmine</b> increase vasopressor actions; <b>chlorpropamide,</b>
<b>clofibrate,</b>
<b>carbamazepine,</b>
<span class="classification">thiazide diuretics</span> may increase antidiuretic activity. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Duration:</span> 28 h in aqueous solution, 4872 h in oil, 3060 min IV infusion. <span class="typehead">Distribution:</span> Extracellular fluid. <span class="typehead">Metabolism:</span> Metabolized in liver and kidneys. <span class="typehead">Elimination:</span> Excreted in urine. <span class="typehead">Half-Life:</span> 1020 min. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor infants and children closely. They are more susceptible to volume disturbances (such as sudden reversal of polyuria)
            than adults.
         </li>
<li>Establish baseline data of BP, weight, I&amp;O pattern and ratio. Monitor BP and weight throughout therapy. (Dose used to stimulate
            diuresis has little effect on BP.) Report sudden changes in pattern to physician.
         </li>
<li>Be alert to the fact that even small doses of vasopressin may precipitate MI or coronary insufficiency, especially in older
            adult patients. Keep emergency equipment and drugs (antiarrhythmics) readily available.
         </li>
<li>Check patient's alertness and orientation frequently during therapy. Lethargy and confusion associated with headache may signal
            onset of water intoxication, which, although insidious in rate of development, can lead to convulsions and terminal coma.
         </li>
<li>Monitor urine output, specific gravity, and serum osmolality while patient is hospitalized.</li>
<li>Withhold vasopressin, restrict fluid intake, and notify physician if urine-specific gravity is 
      </li></ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Be prepared for possibility of anginal attack and have coronary vasodilator available (e.g., nitroglycerin) if there is a
            history of coronary artery disease. Report to physician.
         </li>
<li>Measure and record data related to polydipsia and polyuria. Learn how to determine specific gravity and how to keep an accurate
            record of output. Understand that treatment should diminish intense thirst and restore undisturbed normal sleep.
         </li>
<li>Avoid concentrated fluids (e.g., undiluted syrups), since these increase urine volume.</li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>